Dopamine News and Research

Latest Dopamine News and Research

Diamond-coated electrodes for implantable devices

Diamonds adorning tiaras to anklets are treasures but these gemstones inside the body may prove priceless.

6 Oct 2010

McGill University joins two leading Swiss research institutions to enhance neuroscience research

Building on its worldwide reputation as a leader in neuroscience research, McGill University today joined with two leading Swiss research institutions - the University of Zurich (UZH) and the Swiss Federal Institute of Technology (ETHZ) - to enhance neuroscience research in a host of areas, in fields that include pain therapy, Alzheimer's disease, synapse modelling and repair, neuroimmunology and genetic mechanisms of brain diseases.

5 Oct 2010

Research on spatial memories may lead to potential treatments for addiction and obesity

A researcher from the Faculty of Medicine & Dentistry at the University of Alberta has discovered a mechanism underlying some forms of obesity and addictions which could lead to a treatment for both diseases.

5 Oct 2010

New SymPath kit measures DBH activity of Sympathetic Nervous System

Biotech Corporation in acquiring licenses to commercialize 12 Neuro-biomarkers has first focused on SymPath(R) and is now ready to give you the opportunity to shed some light about this Neuro-biomarker of the Sympathetic Nervous System (SNS). Here is a peak into the research behind the Neuro-blood testing that will be available to all patients through their health system.

4 Oct 2010

Neupro improves quality of life in Parkinson's disease patients

People with Parkinson's disease who used once-daily Neupro® (rotigotine) in the RECOVER trial achieved improvements in quality of life, in addition to previously reported beneficial effects on motor and non-motor symptoms.

4 Oct 2010

Intra-Cellular Therapies demonstrates ability of ITI-002 to improve motor and non-motor behaviors in PD

Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor.

1 Oct 2010

Study indicates neurotransmitters are abnormal in people with psychotic illness

There is growing evidence that two neurotransmitters - dopamine and glutamate - are abnormal in people with psychotic illness, including schizophrenia. Among many other things, these chemicals play a role in cognitive functions, such as memory, learning, and problem-solving.

1 Oct 2010

New approach to prevent psychotic symptoms

New research has linked psychosis with an abnormal relationship between two signalling chemicals in the brain. The findings, published in tomorrow's edition of the journal Biological Psychiatry, suggest a new approach to preventing psychotic symptoms, which could lead to better drugs for schizophrenia.

30 Sep 2010

Study suggests drugs targeting glutamatergic transmission may help treat psychotic illness

There is growing evidence that two neurotransmitters dopamine and glutamate are abnormal in people with psychotic illness, including schizophrenia. Among many other things, these chemicals play a role in cognitive functions, such as memory, learning, and problem solving.

30 Sep 2010

Researchers explain why obesity is resistant to treatment

New research provides evidence of the vicious cycle created when an obese individual overeats to compensate for reduced pleasure from food.Obese individuals have fewer pleasure receptors and overeat to compensate, according to a study by University of Texas at Austin senior research fellow and Oregon Research Institute senior scientist Eric Stice and his colleagues published this week in The Journal of Neuroscience.

30 Sep 2010

Synosia's SYN-118 HPPD inhibitor beneficial for Parkinson's patients: Study

Synosia Therapeutics today announced the first clinical study results showing that SYN-118 provides clinically meaningful benefits to Parkinson's patients, has a good safety profile and is well tolerated. Results from an open-label, proof-of-mechanism study of SYN-118 (CL02) were presented at the World Parkinson Congress in Glasgow, Scotland.

29 Sep 2010

XenoPort to present XP21279 clinical trial data at World Parkinson Congress meeting

XenoPort, Inc. announced today that new data from its first clinical trial of XP21279, a Transported Prodrug of L-Dopa, in Parkinson's disease patients will be presented at the upcoming World Parkinson Congress meeting in Glasgow, Scotland.

29 Sep 2010

Higher education levels increases need for symptomatic control of Parkinson's disease

Individuals who have higher levels of education and who are more impaired by Parkinson's disease appear to require treatment for their symptoms earlier than do other patients, according to a report posted online today that will appear in the September print issue of Archives of Neurology, one of the JAMA/Archives journals.

28 Sep 2010

Researchers explain how nerve cells transmit electrical signals

Billions of brain cells are communicating at any given moment. Like an organic supercomputer they keep everything going, from breathing to solving riddles, and "programming errors" can lead to serious conditions such as schizophrenia, Parkinson's disease and attention-deficit hyperactivity disorder.

22 Sep 2010

NIDA awards 5-year, $3.7M research grant for development of drug to treat cocaine addiction

The University of Maryland School of Pharmacy has received a prestigious $3.7 million grant to develop a drug to treat cocaine addiction based on an active ingredient found in some Chinese prescription medicines.

21 Sep 2010

Santarus, VeroScience enter agreement to commercialize CYCLOSET drug for type 2 diabetes

Santarus, Inc., S2 Therapeutics, Inc. and VeroScience LLC today announced that they have entered into a distribution and license agreement granting Santarus exclusive rights to manufacture and commercialize CYCLOSET (bromocriptine mesylate) tablets in the U.S.

9 Sep 2010

Yeast can be simple model to study molecular basis of Parkinson’s disease

Yeast could be a powerful ally in the discovery of new therapeutic drugs to treat Parkinson's disease says a scientist presenting his work at the Society for General Microbiology's autumn meeting in Nottingham today.

8 Sep 2010

Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase IIb protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin for the treatment of major depressive disorder (MDD).

7 Sep 2010

European Commission approves MSD's MAA for SYCREST in manic episodes associated with bipolar I disorder

MSD announced today that the European Commission has approved the Marketing Authorization Application (MAA) for SYCREST® (asenapine) sublingual tablets for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. Today's decision was based on recommendations from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). The Commission Decision applies to all 27 European Member States.

3 Sep 2010

Nabi Biopharmaceuticals, Diosynth sign long-term commercial manufacturing agreement

Nabi Biopharmaceuticals announced today that it has entered into a long-term commercial manufacturing agreement with Diosynth RTP, Inc. for the manufacture of Drug Substance integral to the production of NicVAX, Nabi's innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse.

2 Sep 2010

Dopamine News and Research

Latest Dopamine News and Research

Diamond-coated electrodes for implantable devices

McGill University joins two leading Swiss research institutions to enhance neuroscience research

Research on spatial memories may lead to potential treatments for addiction and obesity

New SymPath kit measures DBH activity of Sympathetic Nervous System

Neupro improves quality of life in Parkinson's disease patients

Intra-Cellular Therapies demonstrates ability of ITI-002 to improve motor and non-motor behaviors in PD

Study indicates neurotransmitters are abnormal in people with psychotic illness

New approach to prevent psychotic symptoms

Study suggests drugs targeting glutamatergic transmission may help treat psychotic illness

Researchers explain why obesity is resistant to treatment

Synosia's SYN-118 HPPD inhibitor beneficial for Parkinson's patients: Study

XenoPort to present XP21279 clinical trial data at World Parkinson Congress meeting

Higher education levels increases need for symptomatic control of Parkinson's disease

Researchers explain how nerve cells transmit electrical signals

NIDA awards 5-year, $3.7M research grant for development of drug to treat cocaine addiction

Santarus, VeroScience enter agreement to commercialize CYCLOSET drug for type 2 diabetes

Yeast can be simple model to study molecular basis of Parkinson’s disease

Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder

European Commission approves MSD's MAA for SYCREST in manic episodes associated with bipolar I disorder

Nabi Biopharmaceuticals, Diosynth sign long-term commercial manufacturing agreement

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Dopamine News and Research

Latest Dopamine News and Research

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Newsletters you may be interested in